Palvella Therapeutics, Inc. (PVLA): R&D Expense
$22.84M
Year ended 2025-12-31
$35.46M
Trailing 12 months to 2026-06-30
-24.5%
3-year compound annual growth
-13.3%
5-year compound annual growth
+10.7%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.84M | +180.2% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $8.15M | -7.3% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $8.79M | -83.4% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $52.98M | -20.5% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $66.66M | +43.3% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $46.53M | -15.4% | 2022-03-02, From 2020-01-01 |
| 2019-12-31 | $55.00M | +32.6% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $41.49M | +86.2% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $22.29M | +13.1% | 2019-03-18, From 2017-01-01 |
| 2016-12-31 | $19.70M | +138.9% | 2018-03-15, From 2016-01-01 |
| 2015-12-31 | $8.24M | +47.2% | 2017-03-30, From 2015-01-01 |
| 2014-12-31 | $5.60M | -40.5% | 2016-03-23, From 2014-01-01 |
| 2013-12-31 | $9.41M | n/a | 2015-03-30, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $22.84M | +180.2% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $107.0K | -82.0% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $77.00M | -33.8% |
| Scynexis Inc (SCYX) | 2025-12-31 | $22.28M | -15.6% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $7.98M | +10.9% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $20.20M | -24.3% |
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | $61.98M | -47.5% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $24.61M | +29.2% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $19.16M | -60.2% |
Compare PVLA, PRPH, ALXO, SCYX side by side · Screen every company in Pharmaceutical Preparations ↗